
|Videos|November 1, 2021
Interesting Trials in HER2+ Breast Cancer
Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.
Advertisement
Data from the following clinical trials are discussed:
- LBA15 - Primary outcome of the phase 3 SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pretreated HER2-positive locally advanced or metastatic breast cancer
- 139P - HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
Advertisement
Related to this article

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
2
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
3
Dr Nunnery on Chemo De-Escalation, Ovarian Function Suppression, and Toxicity Management in Breast Cancer
4
NATALEE 6-Year OS Data and Novel ADCs in Breast Cancer Take Center Stage at ESMO 2026
5

